2026-05-13 18:48:28
Latest Post
Bliss GVS Pharma Limited recommends final dividend of Rs. 1
Huhtamaki India Ltd Q1 2026 Net Sales Rs. 5,936 million, EBIT margin 6.5% 
Sri Lotus Developers and Realty Limited recommends final dividend of Rs. 0.50
Thomas Cook India Limited recommends dividend of Rs. 0.50
High Energy Batteries India Ltd recommends dividend of Rs. 3
Research
Buy Jyothy Labs - Karvy
Posted On : 2012-10-20 22:36:27( TIMEZONE : IST )
Jyothy Labs: (CMP: Rs. 172; Target Price: Rs. 201) - BUY
We are bullish on long-term business outlook on account of Jyothy's higher focus on product development, synergy benefits through Henkel India acquisition, better Rural: Urban mix and scope of improvement in EBITDA margin. Jyothy's core business is expected to deliver ~20% CAGR during FY12-15E. Meanwhile, as the Company has almost turnaround Henkel India's performance, we expect better sales growth from Henkel India on account of price hike and increase in the distribution reach.
Outlook & Valuation: We reiterate our "BUY" recommendation on Jyothy Labs and our target price of Rs. 201 apiece is based on 19x P/E of 24-month forward earnings.
